【摘要】 目的:研究风湿性心脏病并发心房颤动患者应用胺碘酮治疗的安全性。方法:将137例风湿性心脏病并发心房颤动患者,根据美国心脏病协会1992年修订的Jone标准分为显著风湿活动组:62例;可疑风湿活动组:47例;无风湿活动组:28例。137例均口服胺碘酮,观察室性心动过速的发生情况,分析室性心动过速与风湿活动、瓣膜病种类、心功能状态、二尖瓣瓣口面积及左房大小的关系。结果:多形性室性心动过速的发生与显著风湿活动有显著性关系,但与瓣膜病的种类、心功能状态、二尖瓣瓣膜口面积及左房大小无相关关系。结论:风湿性心脏病心房颤动患者存在风湿活动时,应慎用胺碘酮。更多还原

【Abstract】 Objective:To investigate the safety of amiodarone on patients with rapid atrial fibrillation associated with rheumatic heart disease. Method:137 cases of patients with rheumatic heart disease compucating rapid atrial fibrillation, were diveded into three groups:active rheumatism group(n=62) doubtful active rheumatism group(n=47) and no active rheumatism group (n=28),Amiodarone was administered to each case orally, the occurrence of ventricular tachycardia was monitored. The relationship among ventricular tachycardia and active rheumatism, the kinds of valve disease, the heart function, the area of mitral orifize and the size of left atrial was analyied. Result:There was relationship between ventricular tachy cardia with active rheumatism, but was no relationship with the sorts of valve disease, the heart function, the area of mitral orifize and the size of left atrial. Conclusion: Amiodarone should be taken cautiously on the patients with active rheumatic heart disease complicating rapid atrial fibrillation.更多还原